Head-To-Head Contrast: Accuray (ARAY) and Invivo Therapeutics (NVIV)

Accuray (NASDAQ: ARAY) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Accuray and Invivo Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray 1 2 4 0 2.43
Invivo Therapeutics 0 1 0 0 2.00

Accuray currently has a consensus target price of $7.17, suggesting a potential upside of 73.74%. Invivo Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 581.82%. Given Invivo Therapeutics’ higher possible upside, analysts plainly believe Invivo Therapeutics is more favorable than Accuray.

Insider and Institutional Ownership

78.9% of Accuray shares are owned by institutional investors. Comparatively, 12.8% of Invivo Therapeutics shares are owned by institutional investors. 3.9% of Accuray shares are owned by company insiders. Comparatively, 3.9% of Invivo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Accuray and Invivo Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accuray $383.41 million 0.90 -$29.57 million ($0.34) -12.13
Invivo Therapeutics N/A N/A -$23.43 million ($0.85) -1.04

Invivo Therapeutics has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Accuray and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accuray -7.49% -55.18% -6.33%
Invivo Therapeutics N/A -134.23% -109.16%

Risk and Volatility

Accuray has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 3.2, meaning that its stock price is 220% more volatile than the S&P 500.

Summary

Accuray beats Invivo Therapeutics on 7 of the 11 factors compared between the two stocks.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply